abstract |
An antibody or antigen-binding fragment thereof that specifically binds human Mer tyrosine kinase (MERTK), comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein: ( i) the VH comprises a complementarity determining region (CDR) 1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 6 and a VH CDR3 of SEQ ID NO: 11, and the VL comprises a CDR1 of SEQ ID NO: 15, a CDR2 of SEQ ID NO: 19 and a CDR3 of SEQ ID NO: 22, in which the CDRs are defined according to the definition of Kabat; (ii) the VH comprises a CDR1 of SEQ ID NO: 2, a CDR2 of SEQ ID NO: 7 and a CDR3 of SEQ ID NO: 12, and the VL comprises a CDR1 of SEQ ID NO: 16, a CDR2 of SEQ ID NO: 20 and a CDR3 of SEQ ID NO: 23, wherein the CDRs are defined according to the definition of Chothia; (iii) the VH comprises a CDR1 of SEQ ID NO: 3, a CDR2 of SEQ ID NO: 8 and a CDR3 of SEQ ID NO: 11, and the VL comprises a CDR1 of SEQ ID NO: 15, a CDR2 of SEQ ID NO: 19 and a CDR3 of SEQ ID NO: 22, wherein the CDRs are defined according to the definition of AbM; (iv) the VH comprises a CDR1 of SEQ ID NO: 4, a CDR2 of SEQ ID NO: 9 and a CDR3 of SEQ ID NO: 13, and the VL comprises a CDR1 of SEQ ID NO: 17, a CDR2 of SEQ ID NO: 21 and a CDR3 of SEQ ID NO: 24, wherein the CDRs are defined according to the definition of Contact; (v) the VH comprises a CDR1 of SEQ ID NO: 5, a CDR2 of SEQ ID NO: 10 and a CDR3 of SEQ ID NO: 14, and the VL comprises a CDR1 of SEQ ID NO: 18, a CDR2 of SEQ ID NO: 20 and a CDR3 of SEQ ID NO: 22, wherein the CDRs are defined according to the definition of IMGT; or (vi) the VH comprises a CDR1 of SEQ ID NO: 3, a CDR2 of SEQ ID NO: 6 and a CDR3 of SEQ ID NO: 11, and the VL comprises a CDR1 of SEQ ID NO: 15, a CDR2 of SEQ ID NO: 19 and a CDR3 of SEQ ID NO: 22, wherein the CDRs are defined according to the definition by way of example. |